Published in J Neural Transm Suppl on January 01, 1980
Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry (1995) 1.47
Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles. Acta Neuropathol (1990) 1.17
The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry (1988) 1.15
The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol (1993) 1.13
Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J (1988) 1.07
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Further observations on Tau-positive glia in the brains with progressive supranuclear palsy. Acta Neuropathol (1993) 1.04
Neurofibrillary pathology in progressive supranuclear palsy. Acta Neuropathol (1980) 1.02
Familial progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (1993) 0.98
Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol (1998) 0.91
Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. Acta Neuropathol (1994) 0.90
Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (1991) 0.88
Occurrence of 15-nm-wide straight tubules in neocortical neurons in progressive supranuclear palsy. Acta Neuropathol (1989) 0.85
Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer's disease or progressive supranuclear palsy. Acta Neuropathol (1994) 0.81
Is brain banking of psychiatric cases valuable for neurobiological research? Clinics (Sao Paulo) (2008) 0.81
Modified tau is present in younger nondemented persons: a study of subcortical nuclei in Alzheimer's disease and progressive supranuclear palsy. Acta Neuropathol (1991) 0.80
Unusual case of corticobasal degeneration with tau/Gallyas-positive neuronal and glial tangles. Acta Neuropathol (1994) 0.77
Immunohistochemical study of a case with progressive supranuclear palsy without ophthalmoplegia. Acta Neuropathol (1992) 0.76
Parkinsonism and tremor disorders. A clinical approach. Libyan J Med (2007) 0.75
Progressive supranuclear palsy and In111-DTPA cisternography. J Neurol Neurosurg Psychiatry (1984) 0.75
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res (1994) 4.15
Array-based genomic resequencing of human leukemia. Oncogene (2010) 3.77
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron (1991) 2.05
CNTF and endogenous psychoses? Nat Genet (1996) 2.02
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Neuroaxonal dystrophy in man: character and natural history. Acta Neuropathol (1971) 1.89
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Flexible endoneurosurgical therapy for aqueductal stenosis. Neurosurgery (1993) 1.77
High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci U S A (1986) 1.76
Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood (1999) 1.73
ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol (2008) 1.71
Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol (1999) 1.71
Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (1977) 1.70
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol (1991) 1.69
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study. J Neurol Neurosurg Psychiatry (1987) 1.62
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry (1996) 1.58
Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol (1998) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol (2001) 1.57
Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52
An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol (1989) 1.51
Immunocytochemical and ultrastructural studies of Pick's disease. Ann Neurol (1990) 1.51
Biosynthetic (recombinant) human granulocyte-macrophage colony-stimulating factor: effect on normal bone marrow and leukemia cell lines. Blood (1986) 1.51
No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol (2000) 1.49
Neurofibrillary tangles in human upper cervical ganglia. Morphological study with immunohistochemistry and electron microscopy. Acta Neuropathol (1987) 1.48
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Hepatic artery pseudoaneurysms in a patient treated for miliary tuberculosis. Intern Med (2000) 1.48
Neuroendoscopic approach to tectal tumors: a consecutive series. J Neurosurg (1999) 1.48
A unique case of t(15;17) acute promyelocytic leukaemia (M3) developing into acute myeloblastic leukaemia (M1) with t(7;21) at relapse. Br J Haematol (1993) 1.46
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Vascular malformations of the central nervous system: a morphological overview. Neurosurg Rev (1986) 1.45
Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (1998) 1.45
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 1.44
Low prevalence of Helicobacter pylori in individuals with HTLV-I infection. Eur J Gastroenterol Hepatol (1999) 1.43
Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood (1995) 1.42
A new neurosurgical ventriculoscope--technical note. Neurol Med Chir (Tokyo) (1990) 1.41
Immunocytochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral sclerosis. Ann Neurol (1990) 1.40
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40
Acute myeloid leukaemia with t(9;11)(p22;q23) in a patient treated for adult T cell leukaemia. Br J Haematol (1994) 1.40
[Neuroaxonal dystrophies]. Verh Dtsch Ges Pathol (1968) 1.40
Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (1995) 1.40
Guillain-Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses. Eur J Neurol (2003) 1.39
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37
Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol (2011) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Primary intracranial sarcomas: histopathological features of 19 cases. Histopathology (1991) 1.34
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology (1996) 1.32
Primary malignant lymphomas of the central nervous system in man. Acta Neuropathol Suppl (1975) 1.32
["Striato-nigral degeneration"]. Acta Neuropathol (1968) 1.31
Connatal intracranial tumours. Neuropadiatrie (1973) 1.31
Histochemical and ultrastructural changes in senile human skeletal muscle. J Am Geriatr Soc (1977) 1.31
Ultrastructure of Hirano bodies. Acta Neuropathol (1974) 1.29
Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience (1992) 1.28
Agyria-pachygyria (lissencephaly syndrome). Neuropadiatrie (1976) 1.28
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26